Immunome (NASDAQ:IMNM) Stock Gets Price Target Trim from Stifel Nicolaus

Immunome (NASDAQ:IMNM) had its price target trimmed by Stifel Nicolaus from $24.00 to $23.00 in a report published on Tuesday,Benzinga reports. The firm currently has a hold rating on the stock.

Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, October 15th. Wall Street Zen downgraded Immunome from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Piper Sandler dropped their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Tuesday. William Blair initiated coverage on Immunome in a report on Friday, October 16th. They issued an “outperform” rating for the company. Finally, Truist Financial lifted their price objective on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immunome has an average rating of “Moderate Buy” and a consensus target price of $33.85.

Immunome Trading Down 1.9%

Shares of NASDAQ:IMNM opened at $18.70 on Tuesday. The stock has a fifty day simple moving average of $20.82 and a two-hundred day simple moving average of $22.27. Immunome has a 12-month low of $16.11 and a 12-month high of $30.06. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -7.08 and a beta of 2.68.

Immunome (NASDAQ:IMNM) last released its earnings results on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). As a group, equities research analysts predict that Immunome will post -2.59 EPS for the current year.

Insider Activity

In other news, insider Jack Higgins sold 13,200 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider owned 65,050 shares of the company’s stock, valued at $1,647,066. This represents a 16.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.21% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in IMNM. Allworth Financial LP bought a new position in Immunome in the second quarter worth approximately $25,000. Integrated Wealth Concepts LLC bought a new stake in Immunome during the second quarter valued at about $27,000. Assetmark Inc. increased its position in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Immunome by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock worth $3,997,000 after buying an additional 1,625 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Immunome in the first quarter worth about $60,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Recent Immunome Headlines

Here are a few of the latest headlines about IMNM:

• Positive Sentiment: HC Wainwright kept its Buy rating despite reducing its estimates.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.76 from $0.68, and reduced full-year EPS estimates to losses of $2.64 for 2026, $2.71 for 2027, $2.41 for 2028, $1.63 for 2029, and $0.42 for 2030. The largest revisions include turning its 2029 forecast from a $0.40 profit to a loss, and its 2030 forecast from a $1.08 profit to a loss. These changes signal weaker expected earnings. Immunome analyst estimates
• Negative Sentiment: Piper Sandler cut its price target for Immunome. Piper Sandler price target cut

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.